Scientific Research
Observation on short-term effect and analysis of influencing factors of ranibizumab in the treatment of macular edema secondary to retinal vein occlusion
Zhang Xu, Huang Wenzhi, Ren Guoliang, Shi Feng, Gao Zongyin, Yang Weizhong, Leng Yunxia
Published 2021-08-15
Cite as IMHGN, 2021, 27(16): 2447-2451. DOI: 10.3760/cma.j.issn.1007-1245.2021.16.005
Abstract
ObjectiveTo observe and evaluate the short-term effect of intravitreal injection of ranibizumab in patients with macular edema (ME) caused by retinal vein occlusion (RVO), and to analyze possible risk factors that affect vision improvement.
MethodsA retrospective study was conducted on the clinical data of patients who were diagnosed with RVO and received intravitreal injection of ranibizumab from January to December 2020 in Guangzhou First People's Hospital. Before the operation and 1 month and 3 months after the operation, the changes of best corrected visual acuity (BCVA) and central retinal thickness (CMT) were compared and analyzed. Logistic regression analysis was used to analyze the correlation between the increase of BCVA ≥ 2 lines at the final follow-up and risk factors such as age, gender, course of disease, RVO type, hypertension, hyperglycemia, hyperlipidemia, baseline BCVA, cystoid macular edema, and subretinal fluid.
ResultsA total of 39 cases (39 eyes) meeting the inclusion criteria were included in this study, including 19 males and 20 females, with an age of (61.56±12.27) years old. The baseline BCVA was (0.18±0.16), and it was (0.30±0.20) 1 month after the operation and (0.34±0.20) 3 months after the operation respectively, which were significantly higher than the baseline BCVA (t=2.926, 3.693, both P<0.001). The baseline CMT was (474.67±244.86) μm, and it was (252.46±93.51) μm 1 month after the operation and (229.07±121.22) μm 3 months after the operation respectively, which were significantly lower than the baseline CMT (t=5.294, 5.455, both P<0.001). The effective improvement of visual acuity at the final follow-up was significantly correlated with cystoid macular edema (OR=0.037, 95%CI: 0.002-0.604, P<0.05).
ConclusionsIntravitreal injection of ranibizumab in the treatment of ME caused by RVO has a significant short-term effect, which can effectively reduce the thickness of ME and improve patients' vision. In this study, cystoid macular edema is a risk factor for the effective improvement of visual acuity after the operation.
Key words:
Retinal vein occlusion; Macular edema; Vascular endothelial growth factor; Ranibizumab
Contributor Information
Zhang Xu
Department of Ophthalmology, Guangzhou First People's Hospital, Guangzhou 510180, China
Huang Wenzhi
Department of Ophthalmology, Guangzhou First People's Hospital, Guangzhou 510180, China
Ren Guoliang
Department of Ophthalmology, Guangzhou First People's Hospital, Guangzhou 510180, China
Shi Feng
Department of Ophthalmology, Guangzhou First People's Hospital, Guangzhou 510180, China
Gao Zongyin
Department of Ophthalmology, Guangzhou First People's Hospital, Guangzhou 510180, China
Yang Weizhong
Department of Ophthalmology, Guangzhou First People's Hospital, Guangzhou 510180, China
Leng Yunxia
Department of Ophthalmology, Guangzhou First People's Hospital, Guangzhou 510180, China
